Plus   Neg

Stock Alert: Astrotech Up 10%

Shares of Astrotech Corp. (ASTC) are gaining nearly 10% on Wednesday after the micro-cap company's subsidiary and Cleveland Clinic ink a deal for to develop a rapid COVID-19 breath test.

ASTC is currently trading at $2.3899, down $0.2099 or 9.6284%, on the Nasdaq.

Astrotech said its subsidiary BreathTech Corp. has inked a deal with the Cleveland Clinic Foundation. Under the deal, BreathTech's BreathTest-1000 will be used to compare exhaled breath from individuals who have tested positive on a COVID-19 polymerase chain reaction test with that from subjects who have had a negative COVID-19 PCR test.

The goal of the pilot study will be to analyze different volatile organic compounds from the breath to evaluate the correlation with different disease states.

For comments and feedback contact: editorial@rttnews.com

Invest in the Best Biotech Stocks by Subscribing to RTT Biotech Investor.
Follow RTT